#Canada #Toronto #ALS Treatment #Specific Biologics #Dualase

Significant Funding Boost for ALS Gene-Editing Therapy

Overview
Specific Biologics, a pioneering biotechnology firm, has recently announced the successful close of its Series A financing, accumulating an impressive $35 million to further its groundbreaking research in gene-editing therapies aimed at amyotrophic lateral sclerosis (ALS). This funding round, which exceeded expectations, was led by Hatteras Venture Partners, with notable contributions from foundational investors such as Lumira Ventures and adMare BioInnovations, alongside several new investors.

Financing Details

The infusion of capital will primarily aid in propelling Specific Biologics' lead candidate, known as Dualase®, through its initial clinical trials. These trials aim to establish a proof-of-concept for clinical biomarkers in ALS patients exhibiting the C9ORF72 genetic mutation. The current landscape of ALS treatments remains bleak, with no authorized therapies available, accentuating the urgency of Specific Biologics' innovative approach.

CEO Brent Stead emphasized the significant milestone achieved through this financing, stating its importance in creating a new, potentially transformative treatment for those affected by ALS, a degenerative condition that leads to the gradual loss of motor functions crucial for daily activities.

Gene-Editing Potential

Gene editing, a revolutionary field in biotechnology, holds the promise of altering the very genetic fabric that contributes to various diseases. However, as noted by Ben Scruggs of Hatteras Venture Partners, many challenges persist, including precision, specificity, and the effective delivery of these therapies. Specific Biologics aims to tackle these issues head-on with its unique Dualase® platform, meticulously designed to extract disease-related DNA repeat expansions without disrupting the essential DNA sequences necessary for biological functions.

This advanced technique could have implications beyond ALS, potentially benefiting over 40 genetic disorders characterized by similar DNA repeat expansions. Nikhil Thatte, Partner at Lumira Ventures, recognized the scientific differentiation that positions Specific Biologics as a pioneer in the sector, expressing growing conviction in the clinical potential of the Dualase® platform.

Dualase® Platform

The Dualase® technology is specifically engineered to address the limitations found in conventional gene-editing practices. By concentrating on precisely shortening the harmful C9ORF72 repeat expansions at the DNA level, the technology aspires to yield long-lasting therapeutic benefits. The compact nature of Dualase® allows efficient delivery systems, like adeno-associated virus (AAV), to transport the treatment directly to affected neurons within the central nervous system.

Preclinical studies have already showcased promising results, with the Dualase® platform achieving near-total collapse of the pathogenic C9ORF72 repeat expansions in patient-derived ALS cell models and relevant animal models, successfully correcting various disease markers without off-target effects.

The Path Ahead

As part of their committed mission, Specific Biologics has assembled a seasoned team well-versed in genome editing, along with a strategic mix of investors who share a vision for transforming groundbreaking science into tangible clinical outcomes. According to Paul Hastings, Board Chair of Specific Biologics, their revolutionary technology has the potential to redefine gene editing's capabilities and unlock new therapeutic options for severe genetic conditions that have long eluded successful treatment.

In conclusion, the infusion of $35 million into Specific Biologics is not just a gamble; it is an investment in hope—the hope of providing effective treatments to patients battling ALS and potentially altering the trajectory of numerous genetic disorders. As the company embarks on this ambitious journey, the scientific community and patients alike will be watching closely, waiting for breakthroughs that could change lives forever.

For further details, visit Specific Biologics' website or follow them on LinkedIn for updates on their progress.